Assessment of HCV-RNA test results and access rates to antiviral treatment in patients with anti-HCV positivity-a 10-year analysis
Open Access
- 1 January 2022
- journal article
- research article
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 52 (6) , 1984-1990
Abstract
Background/aim: Currently, hepatitis C virus (HCV) infection can be cured by direct-acting antivirals (DAAs). In this study, we aimed to find the rate of viremia among patients with a positive anti-HCV test and the rate of antiviral treatment given to viremic patients. We also aimed to reach patients with anti-HCV positivity but not tested for HCV-RNA, and patients, who were diagnosed with HCV-RNA positivity but received no treatment. Materials and methods: In this study, individuals tested for anti-HCV in Tokat Gaziosmanpaşa University Research and Application Hospital in the period between January 2010 and January 2020 were reviewed retrospectively. Anti-HCV positive patients, who were not tested for HCV-RNA, and HCV-RNA positive patients, who did not receive treatment, were called for a follow-up visit in the outpatient clinic. Results: The prevalences of anti-HCV positivity and viremia among patients were 2.24% and 0.67%, respectively. A HCV-RNA test was ordered in 71.7% of the anti-HCV positive patients. Antiviral treatment was not given to 44.4% of the viremic patients. Of the patients, who were called for a follow-up visit in the outpatient clinic, 3.9% attended the visit. Of these patients, 0.8% were HCV-RNA positive and 0.7% received treatment. Conclusion: Although the rate of HCV-RNA testing was relatively high in patients with anti-HCV positivity, almost half of them did not receive treatment. We could reach only one-third of the patients, who were called for a follow-up visit, and only a few patients received treatment. Individuals with anti-HCV positivity should be referred to a specialist without delay and HCV-RNA testing should be performed immediately to achieve HCV elimination targets. The likelihood of difficulties in reaching patients later should be considered.Keywords
This publication has 14 references indexed in Scilit:
- Hepatitis C screening and referral for further investigation and treatment in a tertiary care hospitalThe Journal of Infection in Developing Countries, 2020
- Physician awareness of hepatitis C virus among different departmentsClinical and Experimental Hepatology, 2020
- Hepatitis virus (HCV) diagnosis and access to treatment in a UK cohortBMC Infectious Diseases, 2018
- Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling studyThe Lancet Gastroenterology & Hepatology, 2017
- Evaluation of Dual Therapy in Real Life Setting in Treatment-Naïve Turkish Patients with HCV Infection: A Multicenter, Retrospective StudyBalkan Medical Journal, 2016
- Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP studyClinical Microbiology and Infection, 2015
- Global epidemiology and genotype distribution of the hepatitis C virus infectionJournal of Hepatology, 2014
- Beyond interferon: rationale and prospects for newer treatment paradigms for chronic hepatitis CTherapeutic Advances in Chronic Disease, 2014
- Global distribution and prevalence of hepatitis C virus genotypesHepatology, 2014
- Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001–2008Hepatology, 2011